HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Metformin Is Associated With Reduced Odds for Colorectal Cancer Among Persons With Diabetes.

AbstractINTRODUCTION:
Metformin may be associated with reduced colorectal cancer (CRC) risk, but findings from previous studies have been inconsistent and had insufficient sample sizes to examine whether the association differs by anatomic site. This study examined whether metformin was associated with reduced CRC risk, both overall and stratified by anatomic site, in a large sample of persons with diabetes who underwent colonoscopy.
METHODS:
We performed a case-control study of US Veterans with prevalent diabetes who underwent colonoscopy between 1999 and 2014 using Department of Veterans Affairs electronic health record data. Cases were defined by presence of CRC at colonoscopy, while controls had normal colonoscopy. The primary exposure was metformin use at time of colonoscopy (yes/no). Association of metformin exposure with CRC (further stratified by proximal, distal, or rectal subsite) was examined using multivariable and multinomial logistic regression and summarized by odds ratios (ORs) with 95% confidence intervals (CIs).
RESULTS:
We included 6,650 CRC patients and 454,507 normal colonoscopy patients. CRC cases were older and had lower metformin exposure. Metformin was associated with 8% relative reduction in CRC odds (OR: 0.92, 95% CI: 0.87-0.96). By subsite, metformin was associated with a 14% statistically significant reduced rectal cancer odds (OR: 0.86, 95% CI: 0.78-0.94) but no reduced distal or proximal cancer odds.
DISCUSSION:
Metformin was associated with reduced CRC odds-particularly rectal cancer-in a large sample of persons with diabetes undergoing colonoscopy.
AuthorsJoshua Demb, Armaan Yaseyyedi, Lin Liu, Ranier Bustamante, Ashley Earles, Pradipta Ghosh, J Silvio Gutkind, Andrew J Gawron, Tonya R Kaltenbach, Maria Elena Martinez, Samir Gupta
JournalClinical and translational gastroenterology (Clin Transl Gastroenterol) Vol. 10 Issue 11 Pg. e00092 (11 2019) ISSN: 2155-384X [Electronic] United States
PMID31770138 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Hypoglycemic Agents
  • Metformin
Topics
  • Aged
  • Colorectal Neoplasms (diagnosis, epidemiology, prevention & control)
  • Diabetes Mellitus, Type 2 (drug therapy)
  • Early Detection of Cancer
  • Female
  • Follow-Up Studies
  • Humans
  • Hypoglycemic Agents (pharmacology)
  • Incidence
  • Male
  • Metformin (pharmacology)
  • Middle Aged
  • Odds Ratio
  • Retrospective Studies
  • Risk Assessment (methods)
  • Risk Factors
  • SEER Program
  • United States (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: